Other Consolidated Financial Statement Detail (Tables)

12 Months Ended

Dec. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Supplemental cash flow information

Supplemental disclosure of cash flow information for the years ended December 31, 2022, 2021 and 2020, is as follows:

	For the Years Ended December 31,
(In millions)	2022		2021		2020
Cash paid during the year for:
Interest	$	262.5	$	280.8	$	272.7
Income taxes	932.9		247.9		906.7

Other income (expense), net

Components of other (income) expense, net, are summarized as follows:

	For the Years Ended December 31,
(In millions)	2022		2021		2020
Gain on sale of equity interest in Samsung Bioepis(1)	$	(1,505.4)	$	—	$	—
Litigation settlement agreement and settlement fees	917.0		—		—
Interest income	(89.3)		(11.0)		(42.0)
Interest expense	246.6		253.6		222.5
(Gains) losses on investments, net	277.3		824.9		(685.7)
Foreign exchange (gains) losses, net	35.5		22.4		10.7
Other, net	10.1		5.6		(2.9)
Total other (income) expense, net	$	(108.2)	$	1,095.5	$	(497.4)

(1) Reflects the pre-tax gain, net of transaction costs, recognized from the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 3, Dispositions, to these consolidated financial statements.

Gain (loss) on investments

The following table summarizes our (gains) losses on investments, net that relates to our equity securities held as of December 31, 2022, 2021 and 2020:

	For the Years Ended December 31,
(In millions)	2022		2021		2020
Net (gains) losses recognized on equity securities	$	264.7	$	821.1	$	(693.9)
Less: Net (gains) losses realized on equity securities	—		(10.3)		(12.1)
Unrealized (gains) losses recognized on equity securities	$	264.7	$	831.4	$	(681.8)

Accrued expense and other

Accrued expense and other consists of the following:

	As of December 31,
(In millions)	2022		2021
Revenue-related reserves for discounts and allowances	$	891.6	$	802.1
Employee compensation and benefits	395.6		345.1
Collaboration expense	277.9		324.7
Royalties and licensing fees	209.4		234.7
Other	746.9		828.6
Total accrued expense and other	$	2,521.4	$	2,535.2